• 1
    Des Jarlais D. C., McKnight C., Goldblatt C., Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction 2009; Epub ahead of print 10 February. DOI: 10.1111/j.1360-0443.2008.02465.x.
  • 2
    Hall H. I., Song R., Rhodes P., Prejean J., An Q., Lee L. M. et al. Estimation of HIV incidence in the United States. JAMA 2008; 300: 5209.
  • 3
    Health Outcomes International. Return on Investment in Needle and Syringe Programs in Australia Report. Sydney: Commonwealth Department of Health and Ageing, Health Outcomes International Pty Ltd, National Centre in HIV Epidemiology and Clinical Research; 2002.
  • 4
    Dolan K., McDonald M., Silins E., Topp L. Needle and Syringe Programs: A Review of the Evidence. Canberra: Australian Department of Health and Ageing; 2005.
  • 5
    Tempalski B., Cooper H., Friedman S. R., Des Jarlais D. C., Brady J., Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy 2008; 19: S4758.
  • 6
    Kimber J., Mattick R. P., Kaldor J. M., Van Beek I., Gilmour S., Rance J. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug Alcohol Rev 2008; 27: 60212.